Lilly’s tirzepatide set to compete with Novo in obesity after hitting in Phase III

Lilly’s tirzepatide appears set to challenge Novo for market share in obesity after new Phase III data showed higher doses of the dual agonist provided nearly 20% placebo-adjusted weight reduction.

Eli Lilly and Co. (NYSE:LLY) reported 72-week data from the Phase III SURMOUNT-1 trial that showed the 10 mg and 15 mg doses of tirzepatide achieved 19.5% and 20.9% weight reduction, compared with 3.1% for placebo. The figures are based on treatment-regiment estimand, a statistical method that calculates efficacy regardless of treatment discontinuation...